Korea’s First Industry-Led Forum Dedicated to Neuroscience Drug Development
행사 소개
From ABL Bio’s Grabody-B platform revolutionizing BBB penetration to AriBio’s Fosun Pharma-partnered AR1001 demonstrating promising Phase III results, Korean biopharma are spearheading a new era of innovation in neuroscience therapeutics. But, with persistent challenges spanning unclear targets, multifactorial biology, brain delivery, and biomarker limitations, a significant opportunity remains for Korean biopharma to innovate and differentiate. Therefore, for the first time, the World CNS Summit South Korea will provide a local, industry-focused platform designed to bolster discovery, preclinical, and early clinical development of transformative therapies for neurodegeneration, epilepsy, psychiatric disorders and more.
This is your ultimate opportunity to connect with a 100+ network of Korean neuroscientists, international thought leaders, and global technology providers in a regionally relevant forum. Gain the insights needed to strengthen preclinical proof-of-concept, learn from global scientific experts, understand what will define the next frontier of CNS therapies, and enhance your positioning for future out-licensing and collaboration.
“I look forward to sharing insights on emerging RNA editing approaches to target APOE and exploring new frontiers in overcoming challenging neurological diseases alongside fellow industry experts.”
Seong-Wook Lee,
Chief Executive Officer, Rznomics
“I highly look forward to actively networking with industry leaders, establishing strong synergies, and laying the groundwork for future technology licensing opportunities to accelerate the delivery of next-generation CNS therapeutics.”
Kwon Min-Soo, Chief Executive Officer, Brainimmunex
“I am highly looking forward to joining the World CNS Summit South Korea to connect with fellow industry pioneers and global leaders. This summit provides an invaluable platform to share breakthrough insights and foster strategic collaborations that can accelerate the development of next-generation CNS therapies.”
Jin Gyu Choi, Head of Research, Mthera Pharma
Unmissable Event Highlights
놓칠 수 없는 행사 하이라이트
Pharma Investment Panel
Learn what S&E and External Innovation leaders from Takeda, Novartis and Eli Lilly are seeking when evaluating the Korean landscape of novel CNS targets and modalities.
New & Unpublished Data Readouts
Access cutting-edge data readouts from AriBio, Mthera Pharma, ADEL, JCR Pharmaceuticals, Genuv and more.
BBB Delivery Case Studies: TfR1 & Beyond
Hear ABL Bio present on IGF1R-mediated transcytosis and distinct endocytic pathways to enable robust BBB transport in APOE4 genotype populations.
Pharma Innovation Spotlights
Hear from international pharma R&D heads from the likes of Lundbeck, Johnson & Johnson, AbbVie and Angelini Pharma, spotlighting their CNS pipeline innovation and strategic priorities in 2026 and beyond.
Korea-China Partnership Case Study
Following AriBio’s recent out-licensing of AR1001 to Fosun Pharma at Phase III, learn how they navigated complex regulatory and geopolitical friction to streamline collaboration.
AOCs Workshop Deep-Dive
Discuss the emerging potential of antibody-oligonucleotide conjugates for enhanced BBB penetrance with JCR Pharmaceuticals, ABL Bio and Angelini Pharma.
Explore the Full Event Guide
공식 아젠다를 다운로드하여 다음 내용을 확인하세요
- Cutting-edge insights from pioneering Korean innovators, alongside voices from Japan, China, US, India and Europe
- Presentations containing new data from AriBio, Mthera Pharma, ADEL, JCR Pharmaceuticals, Genuv and more
- Dedicated networking opportunities with global experts working on neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders
- Strategic investment insights from global representatives at Novartis, Takeda, Eli Lilly, Johnson & Johnson and more
Attending Companies Include
참석 기업에는 다음이 포함됩니다
Explore the Agenda
Hear the latest CNS innovations taking place within South Korea while hearing from global experts.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean neuroscience drug developers.
Join Biopharma Experts
Be part of the hottest conversations with like-minded neuroscientists, C-level executives, heads, VPs, and more across discovery, translational and clinical development.